Fusion Antibodies (LON:FAB) Issues Earnings Results

Fusion Antibodies (LON:FAB) posted its quarterly earnings results on Monday. The company reported GBX (1.20) EPS for the quarter, Digital Look Earnings reports. Fusion Antibodies had a negative net margin of 91.92% and a negative return on equity of 210.32%.

Fusion Antibodies Stock Performance

LON FAB traded down GBX 1.70 during mid-day trading on Monday, reaching GBX 9.65. 1,905,496 shares of the stock were exchanged, compared to its average volume of 415,646. The business’s 50 day moving average is GBX 10.89 and its 200-day moving average is GBX 12.20. The company has a debt-to-equity ratio of 92.42, a quick ratio of 2.36 and a current ratio of 1.80. Fusion Antibodies has a 1 year low of GBX 9.10 and a 1 year high of GBX 21. The company has a market capitalization of £12.08 million, a P/E ratio of -6.43 and a beta of 1.24.

About Fusion Antibodies

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.